[Azithromycin as a novel treatment for bronchiolitis obliterans syndrome].

Abstract

Bronchiolitis obliterans syndrome (BOS) is one of the main causes of mortality after lung and bone marrow transplantation. Up to 75% of lung transplantation patients develop BOS within 5 years, whereas after bone marrow transplantation 14% of the patients develop the disease with 65% mortality within 3 years. Patients demonstrate gradual decrease in pulmonary functions with no significant anatomic/imagine findings. Therapeutic trials with high dose systemic corticosteroids, immune suppression and immunomodulation did not show any significant success. However, macrolides and especially azithromycin have recently been reported as highly efficient for BOS. This review summarizes information on the disease focusing on the clinical experience with azithromycin as a treatment for BOS.

• Authors: Nir Peled, David Shitrit, Daniele Bendayan, Mordechai R Kramer
• Journal: Harefuah (Harefuah) Vol. 146 Issue 3 Pg. 219-22, 245 (Mar 2007) ISSN: 0017-7768 [Print] Israel
• PMID: 17460931 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Antitubercular Agents
• Azithromycin

Topics

• Anti-Bacterial Agents (therapeutic use)
• Antitubercular Agents (therapeutic use)
• Azithromycin (therapeutic use)
• Bronchiolitis Obliterans (drug therapy)
• Humans
• Tuberculin Test
• Tuberculosis (therapy)